

Salim Abdool Karim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4782683/publications.pdf>

Version: 2024-02-01

435
papers

28,903
citations

7096

78
h-index

7518

151
g-index

453
all docs

453
docs citations

453
times ranked

23705
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa. <i>Current HIV/AIDS Reports</i> , 2022, 19, 46-53.	3.1	26
2	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. <i>Journal of Infectious Diseases</i> , 2022, 226, 510-520.	4.0	13
3	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	11.0	153
4	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. <i>BMJ Open</i> , 2022, 12, e052880.	1.9	18
5	Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial. <i>EClinicalMedicine</i> , 2022, 44, 101298.	7.1	4
6	Genital immune cell activation and tenofovir gel efficacy: a case-control study. <i>Clinical Infectious Diseases</i> , 2022, , .	5.8	2
7	Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression. <i>Scientific Reports</i> , 2022, 12, 2437.	3.3	6
8	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	1.0	1
9	Age-Restriction of a Validated Risk Scoring Tool Better Predicts HIV Acquisition in South African Women: CAPRISA 004. <i>AIDS and Behavior</i> , 2022, , 1.	2.7	0
10	COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. <i>BMJ Global Health</i> , 2022, 7, e009010.	4.7	29
11	Public understanding of science: Communicating in the midst of a pandemic. <i>Public Understanding of Science</i> , 2022, 31, 282-287.	2.8	5
12	Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969.	6.3	120
13	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. <i>Journal of Infectious Diseases</i> , 2021, 223, 370-380.	4.0	50
14	Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. <i>Journal of Investigative Medicine</i> , 2021, 69, 28-40.	1.6	4
15	Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 221-225.	2.1	12
16	Future scenarios for the COVID-19 pandemic. <i>Lancet, The</i> , 2021, 397, 777-778.	13.7	127
17	Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. <i>Sexually Transmitted Infections</i> , 2021, 97, 555-565.	1.9	8
18	Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa. <i>Frontiers in Immunology</i> , 2021, 12, 631094.	4.8	7

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 variants and ending the COVID-19 pandemic. <i>Lancet, The</i> , 2021, 397, 952-954.	13.7	462
20	Genital and systemic immune effects of the injectable, contraceptive norethisterone enanthate (NET-EN), in South African women. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13411.	1.2	1
21	Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. <i>Lancet, The</i> , 2021, 397, 947-950.	13.7	26
22	Engaging young women in Africa for PrEP use and adherence. <i>Lancet HIV,the</i> , 2021, 8, e122-e123.	4.7	2
23	Commentary title: COVID-19 research, Africa, and global health. <i>Journal of Virus Eradication</i> , 2021, 7, 100030.	0.5	1
24	Appropriate names for COVID-19 variants. <i>Science</i> , 2021, 371, 1215-1215.	12.6	16
25	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. <i>Lancet, The</i> , 2021, 397, 1263-1264.	13.7	49
26	Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. <i>Lancet HIV,the</i> , 2021, 8, e216-e224.	4.7	15
27	New SARS-CoV-2 Variants – Clinical, Public Health, and Vaccine Implications. <i>New England Journal of Medicine</i> , 2021, 384, 1866-1868.	27.0	581
28	Institutional and behaviour-change interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic. <i>International Health</i> , 2021, 13, 399-409.	2.0	41
29	Epigenetic Regulation of BST-2 Expression Levels and the Effect on HIV-1 Pathogenesis. <i>Frontiers in Immunology</i> , 2021, 12, 669241.	4.8	4
30	Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women. <i>Frontiers in Immunology</i> , 2021, 12, 695201.	4.8	7
31	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , 2021, 73, 1528-1531.	5.8	4
32	Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. <i>Journal of the International AIDS Society</i> , 2021, 24, e25766.	3.0	5
33	HIV incidence trends in Africa: young women at highest risk. <i>Lancet HIV,the</i> , 2021, 8, e389-e390.	4.7	7
34	Exploring discrepant knowledge of partner sexual behaviour to inform self-risk assessment in a high HIV burdened district in rural KwaZulu-Natal. <i>Global Public Health</i> , 2021, , 1-16.	2.0	0
35	Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. <i>Frontiers in Immunology</i> , 2021, 12, 730986.	4.8	25
36	A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcare clinics in South Africa. <i>Journal of the International AIDS Society</i> , 2021, 24, e25803.	3.0	5

#	ARTICLE	IF	CITATIONS
37	Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant. <i>New England Journal of Medicine</i> , 2021, 384, e14.	27.0	3
38	Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. <i>BMJ Open</i> , 2021, 11, e050116.	1.9	7
39	COVID-19 in Africa: Catalyzing change for sustainable development. <i>PLoS Medicine</i> , 2021, 18, e1003869.	8.4	2
40	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , 2021, 17, e1010046.	4.7	6
41	Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. <i>Lancet, The</i> , 2021, 398, 2126-2128.	13.7	1,057
42	Higher mucosal antibody concentrations in women with genital tract inflammation. <i>Scientific Reports</i> , 2021, 11, 23514.	3.3	3
43	HIV pre-exposure prophylaxis implementation in Africa: some early lessons. <i>The Lancet Global Health</i> , 2021, 9, e1634-e1635.	6.3	3
44	Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women. <i>Mucosal Immunology</i> , 2020, 13, 449-459.	6.0	15
45	Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. <i>Cell Reports</i> , 2020, 33, 108430.	6.4	16
46	The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract. <i>Frontiers in Reproductive Health</i> , 2020, 2, .	1.9	4
47	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. <i>Frontiers in Immunology</i> , 2020, 11, 1274.	4.8	1
48	COVID-19 affects HIV and tuberculosis care. <i>Science</i> , 2020, 369, 366-368.	12.6	54
49	Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa. <i>Scientific Reports</i> , 2020, 10, 13017.	3.3	7
50	Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. <i>Lancet, The</i> , 2020, 396, 1102-1124.	13.7	117
51	Development of a prognostic tool exploring female adolescent risk for HIV prevention and PrEP in rural South Africa, a generalised epidemic setting. <i>Sexually Transmitted Infections</i> , 2020, 96, 47-54.	1.9	12
52	The South African Response to the Pandemic. <i>New England Journal of Medicine</i> , 2020, 382, e95.	27.0	92
53	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. <i>Lancet HIV,the</i> , 2020, 7, e229-e237.	4.7	66
54	Putting women in the centre of the global HIV response is key to achieving epidemic control!. <i>Journal of the International AIDS Society</i> , 2020, 23, e25473.	3.0	9

#	ARTICLE	IF	CITATIONS
55	Assessing a diagnosis tool for bacterial vaginosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1481-1485.	2.9	10
56	Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. <i>Current HIV/AIDS Reports</i> , 2020, 17, 249-258.	3.1	10
57	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. <i>BMJ Open</i> , 2020, 10, e042247.	1.9	25
58	Acceptability of HIV self-testing among men and women in KwaZulu-Natal, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 186-192.	1.2	50
59	Diminished HIV Infection of Target CD4+ T Cells in a Toll-Like Receptor 4 Stimulated in vitro Model. <i>Frontiers in Immunology</i> , 2019, 10, 1705.	4.8	10
60	HIV-1 Epidemic Control – Insights from Test-and-Treat Trials. <i>New England Journal of Medicine</i> , 2019, 381, 286-288.	27.0	54
61	AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 100-112.	4.1	24
62	Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. <i>Viruses</i> , 2019, 11, 569.	3.3	2
63	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , 2019, 9, e030283.	1.9	12
64	HIV incidence rates in adolescent girls and young women in sub-Saharan Africa. <i>The Lancet Global Health</i> , 2019, 7, e1470-e1471.	6.3	71
65	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	141
66	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2019, 22, e25381.	3.0	13
67	Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. <i>JAMA Network Open</i> , 2019, 2, e1914378.	5.9	33
68	Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. <i>Journal of the International AIDS Society</i> , 2019, 22, e25346.	3.0	45
69	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 1441.	3.5	46
70	The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. <i>Journal of the International AIDS Society</i> , 2019, 22, e25300.	3.0	43
71	Asymptomatic Bacterial Vaginosis in Pregnancy and Missed Opportunities for Treatment: A Cross-Sectional Observational Study. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2019, 2019, 1-7.	1.5	12
72	Who is sexually active? Using a multi-component sexual activity profile (MSAP) to explore, identify and describe sexually-active high-school students in rural KwaZulu-Natal, South Africa. <i>BMC Public Health</i> , 2019, 19, 317.	2.9	3

#	ARTICLE	IF	CITATIONS
73	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	7.1	51
74	Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
75	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. <i>Frontiers in Immunology</i> , 2019, 10, 2875.	4.8	20
76	IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. <i>PLoS Pathogens</i> , 2019, 15, e1008064.	4.7	66
77	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , 2019, 10, 5227.	12.8	40
78	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
79	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 129-138.	1.1	21
80	<i>“Youâ€™ll always stay right”</i> understanding vaginal products and the motivations for use among adolescent and young women in rural KZN. <i>Culture, Health and Sexuality</i> , 2019, 21, 95-107.	1.8	2
81	Improving survival with tuberculosis & HIV treatment integration: A mini-review. <i>Indian Journal of Medical Research</i> , 2019, 150, 131.	1.0	6
82	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. <i>Nature Medicine</i> , 2018, 24, 491-496.	30.7	123
83	Identification and validation of a multi-essay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. <i>Journal of the International AIDS Society</i> , 2018, 21, e25082.	3.0	26
84	Integrin $\alpha 4 \beta 7$ expression on peripheral blood CD4 ⁺ T cells predicts HIV acquisition and disease progression outcomes. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	85
85	Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e36-e39.	2.1	4
86	Acceptability of Early Antiretroviral Therapy Among South African Women. <i>AIDS and Behavior</i> , 2018, 22, 1018-1024.	2.7	22
87	The microbiome and HIV prevention strategies in women. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 81-87.	3.8	16
88	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018, 25, 3123-3135.e6.	6.4	23
89	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. <i>Cell Host and Microbe</i> , 2018, 24, 593-599.e3.	11.0	24
90	Exploratory analysis of the ecological variables associated with sexual health profiles in high-risk, sexually-active female learners in rural KwaZulu-Natal. <i>PLoS ONE</i> , 2018, 13, e0195107.	2.5	3

#	ARTICLE	IF	CITATIONS
91	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. <i>Nature Communications</i> , 2018, 9, 4136.	12.8	11
92	Optimising the accuracy of HIV drug resistance assays. <i>Lancet HIV,the</i> , 2018, 5, e608-e609.	4.7	0
93	Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. <i>PLoS ONE</i> , 2018, 13, e0196209.	2.5	81
94	Expert consensus statement on the science of <scp>HIV</scp> in the context of criminal law. <i>Journal of the International AIDS Society</i> , 2018, 21, e25161.	3.0	59
95	Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. <i>PLoS ONE</i> , 2018, 13, e0200359.	2.5	5
96	Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. <i>Lancet HIV,the</i> , 2018, 5, e427-e437.	4.7	60
97	Case report: mechanisms of HIV elite control in two African women. <i>BMC Infectious Diseases</i> , 2018, 18, 54.	2.9	82
98	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. <i>Cell Host and Microbe</i> , 2018, 23, 845-854.e6.	11.0	100
99	Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. <i>Clinical Immunology</i> , 2018, 195, 127-138.	3.2	22
100	HIVâ€™No time for complacency. <i>Science</i> , 2018, 360, 1153-1153.	12.6	9
101	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1006987.	4.7	71
102	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. <i>Lancet HIV,the</i> , 2018, 5, e400-e404.	4.7	75
103	Prevention Clinical Trials: Highlights of Evidence and Research. , 2018, , 1713-1723.		0
104	HIV-1 Preexposure Prophylaxis. , 2018, , 886-892.		0
105	CAPRISA 003: Timing of Antiretroviral Initiation in HIV-TB Co-infected Patientsâ€™The SAPIT Trial. , 2017, , 107-120.		0
106	Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. <i>Journal of Virology</i> , 2017, 91, .	3.4	13
107	Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa. <i>Culture, Health and Sexuality</i> , 2017, 19, 1268-1285.	1.8	18
108	Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. <i>Lancet HIV,the</i> , 2017, 4, e41-e50.	4.7	220

#	ARTICLE	IF	CITATIONS
109	Interleukin 1-Beta (IL-1 β) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 213-220.	2.1	16
110	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, S17-S26.	2.1	80
111	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , 2017, 356, 938-945.	12.6	348
112	Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 43-47.	2.1	5
113	Trump's "global gag rule" implications for human rights and global health. <i>The Lancet Global Health</i> , 2017, 5, e387-e389.	6.3	23
114	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	81
115	Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. <i>Journal of Immunology</i> , 2017, 198, 1220-1228.	0.8	18
116	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. <i>Aids</i> , 2017, 31, 2199-2209.	2.2	13
117	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	87
118	Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women. <i>Aids</i> , 2017, 31, 191-197.	2.2	2
119	Genital "Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 318-325.	2.1	64
120	Closing the NIH Fogarty Center threatens US and global health. <i>Lancet, The</i> , 2017, 390, 451.	13.7	2
121	Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. <i>Journal of Virology</i> , 2017, 91, .	3.4	35
122	Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa. <i>Clinical Infectious Diseases</i> , 2017, 65, 819-826.	5.8	23
123	Assessing progress with HIV incidence in national cohorts. <i>Lancet HIV,the</i> , 2017, 4, e56-e58.	4.7	2
124	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. <i>Clinical Infectious Diseases</i> , 2017, 64, 79-82.	5.8	53
125	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 734-740.	1.2	6
126	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREATment and Monitoring (STREAM) study. <i>BMJ Open</i> , 2017, 7, e017507.	1.9	19

#	ARTICLE	IF	CITATIONS
127	Governmental Support of Research. , 2017, , 679-705.		1
128	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathogens, 2017, 13, e1006148.	4.7	51
129	Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol. Implementation Science, 2017, 12, 129.	6.9	25
130	The Impact of Conditional Cash Transfers in Reducing HIV in Adolescent Girls and Boys (RHIVA): The CAPRISA 007 Matched Pair, Cluster Randomised Controlled Trial. , 2017, , 77-89.		6
131	High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. PLoS ONE, 2017, 12, e0184124.	2.5	13
132	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
133	Current status of the HIV epidemic & challenges in prevention. Indian Journal of Medical Research, 2017, 146, 673.	1.0	7
134	Scaling up TB-HIV Integration in Public Health Clinics: Translating Research Findings into Practice. , 2017, , 121-134.		0
135	Prevention Clinical Trials: Highlights of Evidence and Research. , 2017, , 1-11.		0
136	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. PLoS Biology, 2016, 14, e1002372.	5.6	12
137	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.7	150
138	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. Aids, 2016, 30, 1005-1014.	2.2	18
139	Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e45-e48.	2.1	37
140	Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. Antiviral Therapy, 2016, 22, 287-293.	1.0	2
141	Association of Polymorphisms in the Regulatory Region of the Cyclophilin a Gene (PPIA) with Gene Expression and HIV/AIDS Disease Progression. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 465-473.	2.1	8
142	Factors Driving the HIV Epidemic in Southern Africa. Current HIV/AIDS Reports, 2016, 13, 158-169.	3.1	38
143	Social Context of Adherence in an Open-Label 1% Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. AIDS and Behavior, 2016, 20, 2682-2691.	2.7	12
144	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. Journal of Virology, 2016, 90, 10220-10235.	3.4	32

#	ARTICLE	IF	CITATIONS
145	Combination HIV prevention options for young women in Africa. <i>African Journal of AIDS Research</i> , 2016, 15, 109-121.	0.9	39
146	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	6.1	34
147	Metabolic Syndrome After HIV Acquisition in South African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 438-445.	2.1	26
148	Is the UNAIDS target sufficient for HIV control in Botswana?. <i>Lancet HIV</i> , 2016, 3, e195-e196.	4.7	8
149	Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. <i>Immunity</i> , 2016, 44, 391-405.	14.3	125
150	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , 2016, 9, 821-833.	6.0	22
151	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	6.4	45
152	Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. <i>Sexually Transmitted Infections</i> , 2016, 92, 186-193.	1.9	50
153	Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. <i>Contraception</i> , 2016, 93, 25-31.	1.5	15
154	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	3.4	205
155	Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. <i>Mucosal Immunology</i> , 2016, 9, 194-205.	6.0	205
156	High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South Africa. <i>PLoS ONE</i> , 2016, 11, e0146603.	2.5	40
157	Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists. <i>PLoS ONE</i> , 2016, 11, e0155668.	2.5	5
158	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	4.7	81
159	Efavirenz Dosing: Influence of Drug Metabolizing Enzyme Polymorphisms and Concurrent Tuberculosis Treatment. <i>Antiviral Therapy</i> , 2015, 20, 297-306.	1.0	10
160	Challenges with participant reimbursement: experiences from a post-trial access study. <i>Journal of Medical Ethics</i> , 2015, 41, 909-913.	1.8	6
161	Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 576-584.	2.1	10
162	Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. <i>BMC Infectious Diseases</i> , 2015, 16, 27.	2.9	12

#	ARTICLE	IF	CITATIONS
163	Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. <i>BMC Public Health</i> , 2015, 15, 1149.	2.9	33
164	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on I ₄₂₇ for replication. <i>Retrovirology</i> , 2015, 12, 54.	2.0	19
165	Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 264-269.	2.1	67
166	Antibodies for HIV prevention in young women. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 183-189.	3.8	9
167	Relationship between female genital tract infections, mucosal interleukin-17 production and local T helper type 17 cells. <i>Immunology</i> , 2015, 146, 557-567.	4.4	45
168	Trends in HIV Prevalence in Pregnant Women in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 289-295.	2.1	51
169	Adolescent girls and young women: key populations for HIV epidemic control. <i>Journal of the International AIDS Society</i> , 2015, 18, 19408.	3.0	361
170	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. <i>PLoS ONE</i> , 2015, 10, e0131906.	2.5	26
171	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 55-61.	2.1	10
172	Tenofovir Gel to Prevent HSV-2 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 1980-1981.	27.0	1
173	Individualised Motivational Counselling to Enhance Adherence to Antiretroviral Therapy is not Superior to Didactic Counselling in South African Patients: Findings of the CAPRISA 058 Randomised Controlled Trial. <i>AIDS and Behavior</i> , 2015, 19, 145-156.	2.7	18
174	HIV-1 Superinfection Resembles Primary Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 904-908.	4.0	13
175	Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2015, 373, 875-876.	27.0	26
176	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 530-539.	27.0	80
177	Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. <i>Journal of Immunology</i> , 2015, 195, 2273-2281.	0.8	24
178	Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive. <i>Journal of Reproductive Immunology</i> , 2015, 110, 14-21.	1.9	38
179	Genital Inflammation and the Risk of HIV Acquisition in Women. <i>Clinical Infectious Diseases</i> , 2015, 61, 260-269.	5.8	354
180	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. <i>PLoS Medicine</i> , 2015, 12, e1001778.	8.4	170

#	ARTICLE	IF	CITATIONS
181	Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. <i>AIDS and Behavior</i> , 2015, 19, 1305-1316.	2.7	39
182	HIV-Positive Status Disclosure in Patients in Care in Rural South Africa: Implications for Scaling Up Treatment and Prevention Interventions. <i>AIDS and Behavior</i> , 2015, 19, 322-329.	2.7	20
183	Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. <i>Journal of Immunology</i> , 2015, 194, 4371-4378.	0.8	85
184	Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 212, 754-759.	4.0	36
185	Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1153-1159.	1.1	16
186	Epigenetic mechanisms, T-cell activation, and <i>CCR5</i> genetics interact to regulate T-cell expression of <i>CCR5</i> , the major HIV-1 coreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4762-71.	7.1	48
187	Defeating AIDS—advancing global health. <i>Lancet, The</i> , 2015, 386, 171-218.	13.7	234
188	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015, 21, 1332-1336.	30.7	215
189	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. <i>Journal of Infectious Diseases</i> , 2015, 211, 1461-1466.	4.0	7
190	Health-Related Quality of Life Dynamics of HIV-positive South African Women up to ART Initiation: Evidence from the CAPRISA 002 Acute Infection Cohort Study. <i>AIDS and Behavior</i> , 2014, 18, 1114-23.	2.7	16
191	Implementation of Adolescent-Friendly Voluntary Medical Male Circumcision Using a School Based Recruitment Program in Rural KwaZulu-Natal, South Africa. <i>PLoS ONE</i> , 2014, 9, e96468.	2.5	38
192	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. <i>PLoS ONE</i> , 2014, 9, e101863.	2.5	36
193	Inclusion of adolescent girls in HIV prevention research — an imperative for an AIDS-free generation. <i>Journal of the International AIDS Society</i> , 2014, 17, 19075.	3.0	13
194	Meeting the sexual and reproductive health needs of high-school students in South Africa: Experiences from rural KwaZulu-Natal. <i>South African Medical Journal</i> , 2014, 104, 687.	0.6	11
195	Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1521-1525.	1.2	14
196	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. <i>Trials</i> , 2014, 15, 496.	1.6	9
197	Limited HIV-1 Superinfection in Seroconverters from the CAPRISA 004 Microbicide Trial. <i>Journal of Clinical Microbiology</i> , 2014, 52, 844-848.	3.9	14
198	HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. <i>Sexually Transmitted Infections</i> , 2014, 90, 363-369.	1.9	34

#	ARTICLE	IF	CITATIONS
199	Low rifampicin concentrations in tuberculosis patients with HIV infection. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 987-993.	1.2	35
200	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A20-A21.	1.1	1
201	Appeal to global donors to save the Treatment Action Campaign. <i>Lancet, The</i> , 2014, 384, e62.	13.7	2
202	HIV Infection in High School Students in Rural South Africa: Role of Transmissions Among Students. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 956-965.	1.1	23
203	Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8 ⁺ T Cell Responses on HIV Set Point. <i>Journal of Virology</i> , 2014, 88, 1819-1824.	3.4	36
204	Bacterial Vaginosis and the Risk of <i>Trichomonas vaginalis</i> Acquisition Among HIV-1 ⁻ Negative Women. <i>Sexually Transmitted Diseases</i> , 2014, 41, 123-128.	1.7	75
205	Y Chromosome and HIV DNA Detection in Vaginal Swabs as Biomarkers of Semen and HIV Exposure in Women. <i>Sexually Transmitted Diseases</i> , 2014, 41, 674-679.	1.7	17
206	Rapid Disease Progression in HIV-1 Subtype C ⁺ Infected South African Women. <i>Clinical Infectious Diseases</i> , 2014, 59, 1322-1331.	5.8	46
207	Recombination-mediated escape from primary CD8 ⁺ T cells in acute HIV-1 infection. <i>Retrovirology</i> , 2014, 11, 69.	2.0	27
208	Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 209, 500-509.	4.0	99
209	The need for multipurpose prevention technologies in sub-Saharan Africa. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 27-34.	2.3	35
210	Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 53-61.	2.3	7
211	Mervyn W. Susser - His Contributions to the Acquired Immune Deficiency Syndrome Response in South Africa. <i>Paediatric and Perinatal Epidemiology</i> , 2014, 28, 473-475.	1.7	0
212	Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1916-1920.	4.0	13
213	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	27.8	681
214	TRIM5 ^Δ and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment. <i>Journal of Virology</i> , 2014, 88, 4291-4303.	3.4	21
215	Nelson R. Mandela (1918 [–] 2013). <i>Science</i> , 2014, 343, 150-150.	12.6	4
216	Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. <i>Sexually Transmitted Infections</i> , 2014, 90, 580-587.	1.9	173

#	ARTICLE	IF	CITATIONS
217	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	11.0	137
218	Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure. <i>Virology</i> , 2014, 468-470, 214-225.	2.4	20
219	Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 849-854.	2.7	44
220	Measuring Adherence by Visual Inspection of Returned Empty Gel Applicators in the CAPRISA 004 Microbicide Trial. <i>AIDS and Behavior</i> , 2014, 18, 820-825.	2.7	7
221	Monitoring Microbicide Gel Use with Real-Time Notification of the Container's Opening Events: Results of the CAPRISA Wisebag Study. <i>AIDS and Behavior</i> , 2014, 18, 833-840.	2.7	10
222	Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial. <i>AIDS and Behavior</i> , 2014, 18, 811-819.	2.7	21
223	Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 841-848.	2.7	20
224	Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case-Control Study. <i>AIDS and Behavior</i> , 2014, 18, 826-832.	2.7	9
225	The Preventive Misconception: Experiences from CAPRISA 004. <i>AIDS and Behavior</i> , 2014, 18, 1746-1752.	2.7	8
226	Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the CAPRISA 002 Acute Infection Study. <i>AIDS and Behavior</i> , 2014, 18, 1801-1807.	2.7	18
227	Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. <i>Sexually Transmitted Infections</i> , 2014, 90, 620-626.	1.9	47
228	The HIV Epidemic in Southern Africa – Is an AIDS-Free Generation Possible?. <i>Current HIV/AIDS Reports</i> , 2014, 11, 99-108.	3.1	21
229	Changes to Antiretroviral Drug Regimens during Integrated TB-HIV Treatment: Results of the Sapit Trial. <i>Antiviral Therapy</i> , 2014, 19, 161-169.	1.0	16
230	High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 438-446.	2.1	14
231	Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 147-154.	1.2	29
232	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. <i>Antiviral Therapy</i> , 2013, 18, 301-310.	1.0	21
233	The Global HIV Epidemic: Current Status and Challenges. <i>Current HIV/AIDS Reports</i> , 2013, 10, 111-112.	3.1	10
234	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. <i>Journal of Virology</i> , 2013, 87, 7218-7233.	3.4	119

#	ARTICLE	IF	CITATIONS
235	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. <i>Virology Journal</i> , 2013, 10, 347.	3.4	14
236	Microbicides for the prevention of sexually transmitted HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 12-23.	4.4	11
237	HIV pre-exposure prophylaxis in injecting drug users. <i>Lancet, The</i> , 2013, 381, 2060-2062.	13.7	17
238	Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. <i>Vaccine</i> , 2013, 31, B204-B208.	3.8	26
239	Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial. <i>Antiviral Research</i> , 2013, 99, 405-408.	4.1	2
240	Neither Microbial Translocation Nor TLR Responsiveness Are Likely Explanations for Preexisting Immune Activation in Women Who Subsequently Acquired HIV in CAPRISA 004. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 294-298.	2.1	6
241	Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 97-115.	1.1	10
242	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. <i>PLoS Pathogens</i> , 2013, 9, e1003738.	4.7	190
243	The changing epidemiology of HIV in 2013. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	3.8	78
244	When to start antiretroviral therapy during tuberculosis treatment?. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 35-42.	3.1	37
245	Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies. <i>Journal of Virology</i> , 2013, 87, 4882-4894.	3.4	65
246	Anti-retrovirals for treatment and prevention – time for new paradigms in our response to the HIV/AIDS epidemic?. <i>Developing World Bioethics</i> , 2013, 13, ii-iii.	0.9	6
247	Topical Microbicides – What's New?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S144-S149.	2.1	17
248	Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. <i>Aids</i> , 2013, 27, 507-518.	2.2	14
249	Appropriateness of Hydroxyethylcellulose Gel as a Placebo Control in Vaginal Microbicide Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 120-125.	2.1	19
250	Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection. <i>PLoS ONE</i> , 2013, 8, e53251.	2.5	49
251	Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e56400.	2.5	9
252	No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial. <i>PLoS ONE</i> , 2013, 8, e71758.	2.5	11

#	ARTICLE	IF	CITATIONS
253	Development of Methods for Cross-Sectional HIV Incidence Estimation in a Large, Community Randomized Trial. PLoS ONE, 2013, 8, e78818.	2.5	33
254	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. Journal of Clinical Investigation, 2013, 123, 380-93.	8.2	165
255	Temporal Association of HLA-B*81:01- and HLA-B*39:10-Mediated HIV-1 p24 Sequence Evolution with Disease Progression. Journal of Virology, 2012, 86, 12013-12024.	3.4	20
256	Genital Tract Inflammation During Early HIV-1 Infection Predicts Higher Plasma Viral Load Set Point in Women. Journal of Infectious Diseases, 2012, 205, 194-203.	4.0	67
257	Mucosal Escherichia coli Bactericidal Activity and Immune Mediators Are Associated With HIV-1 Seroconversion in Women Participating in the HPTN 035 Trial. Journal of Infectious Diseases, 2012, 206, 1931-1935.	4.0	21
258	Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness. Journal of Virology, 2012, 86, 13423-13433.	3.4	9
259	Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa. Journal of Infectious Diseases, 2012, 206, 6-14.	4.0	171
260	Preexposure Prophylaxis for HIV Prevention. New England Journal of Medicine, 2012, 367, 462-465.	27.0	9
261	Innate Immune Activation Enhances HIV Acquisition in Women, Diminishing the Effectiveness of Tenofovir Microbicide Gel. Journal of Infectious Diseases, 2012, 206, 993-1001.	4.0	137
262	Increased Memory Differentiation Is Associated with Decreased Polyfunctionality for HIV but Not for Cytomegalovirus-Specific CD8+T Cells. Journal of Immunology, 2012, 189, 3838-3847.	0.8	18
263	A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opinion on Investigational Drugs, 2012, 21, 695-715.	4.1	22
264	Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C<i>gag</i>Vaccine in Healthy HIV-1-Uninfected Adults. Vaccine Journal, 2012, 19, 1651-1660.	3.1	60
265	An AIDS-Free Generation?. Science, 2012, 337, 133-133.	12.6	8
266	Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial. Aids, 2012, 26, 2261.	2.2	4
267	An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clinical Trials, 2012, 9, 377-384.	1.6	2
268	Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. Aids, 2012, 26, 529-532.	2.2	9
269	Natural killer cell function in women at high risk for HIV acquisition. Aids, 2012, 26, 1745-1753.	2.2	14
270	Preservation HIV-1â€“Specific IFNÎ³+ CD4+ T-Cell Responses in Breakthrough Infections After Exposure to Tenofovir Gel in the CAPRISA 004 Microbicide Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 124-127.	2.1	19

#	ARTICLE	IF	CITATIONS
271	The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPiT Trial. <i>Annals of Internal Medicine</i> , 2012, 157, 313.	3.9	101
272	Antiretroviral prophylaxis for HIV prevention reaches a key milestone. <i>Lancet, The</i> , 2012, 379, 2047-2048.	13.7	8
273	Health in South Africa: changes and challenges since 2009. <i>Lancet, The</i> , 2012, 380, 2029-2043.	13.7	396
274	Sustainability of task-shifting for antiretroviral treatment. <i>Lancet, The</i> , 2012, 380, 1907-1908.	13.7	5
275	HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. <i>AIDS and Behavior</i> , 2012, 16, 1870-1876.	2.7	54
276	Evolution of an HIV glycan ^α -dependent broadly neutralizing antibody epitope through immune escape. <i>Nature Medicine</i> , 2012, 18, 1688-1692.	30.7	273
277	HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. <i>BMC Public Health</i> , 2012, 12, 231.	2.9	31
278	HIV prevention. , 2012, , 113-121.		0
279	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	3.4	123
280	CAPRISA 004 Tenofovir Microbicide Trial: No Impact of Tenofovir Gel on the HIV Transmission Bottleneck. <i>Journal of Infectious Diseases</i> , 2012, 206, 35-40.	4.0	16
281	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 689-695.	1.9	50
282	Empowering women in human immunodeficiency virus prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 487-493.	2.8	12
283	Overview of microbicides for the prevention of human immunodeficiency virus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 427-439.	2.8	34
284	Implementing microbicides in low-income countries. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 495-501.	2.8	8
285	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. <i>Journal of Virology</i> , 2011, 85, 4828-4840.	3.4	441
286	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. <i>Journal of Virology</i> , 2011, 85, 3128-3141.	3.4	151
287	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 11502-11519.	3.4	168
288	Co-enrollment in multiple HIV prevention trials ^α Experiences from the CAPRISA 004 Tenofovir gel trial. <i>Contemporary Clinical Trials</i> , 2011, 32, 333-338.	1.8	27

#	ARTICLE	IF	CITATIONS
289	Community-based intervention to increase HIV testing and case detection in people aged 16–32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 525-532.	9.1	204
290	HIV prevention transformed: the new prevention research agenda. <i>Lancet</i> , The, 2011, 378, 269-278.	13.7	238
291	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. <i>Lancet</i> , The, 2011, 378, 279-281.	13.7	220
292	Antiretroviral prophylaxis: a defining moment in HIV control. <i>Lancet</i> , The, 2011, 378, e23-e25.	13.7	84
293	Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. <i>Aids</i> , 2011, 25, 957-966.	2.2	215
294	Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial. <i>Obstetrics and Gynecology</i> , 2011, 118, 895-904.	2.4	32
295	Stigma impedes AIDS prevention. <i>Nature</i> , 2011, 474, 29-31.	27.8	25
296	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. <i>Trials</i> , 2011, 12, 67.	1.6	33
297	Initiating antiretrovirals during tuberculosis treatment: a drug safety review. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 559-574.	2.4	16
298	Duffy-Null Associated Low Neutrophil Counts Influence HIV-1 Susceptibility in High-Risk South African Black Women. <i>Clinical Infectious Diseases</i> , 2011, 52, 1248-1256.	5.8	69
299	Integration of Antiretroviral Therapy with Tuberculosis Treatment. <i>New England Journal of Medicine</i> , 2011, 365, 1492-1501.	27.0	451
300	Virological and Immunological Factors Associated with HIV-1 Differential Disease Progression in HLA-B*58:01-Positive Individuals. <i>Journal of Virology</i> , 2011, 85, 7070-7080.	3.4	25
301	The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. <i>Sexually Transmitted Infections</i> , 2011, 87, 646-653.	1.9	27
302	HIV-Associated Tuberculosis. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	14
303	Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. <i>International Journal of Epidemiology</i> , 2011, 40, 922-930.	1.9	109
304	Case 15-2011. <i>New England Journal of Medicine</i> , 2011, 364, 1956-1964.	27.0	0
305	Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. <i>Aids</i> , 2011, 25, 1711-1719.	2.2	22
306	Experience in international clinical research: the HIV Prevention Trials Network. <i>Clinical Investigation</i> , 2011, 1, 1609-1618.	0.0	14

#	ARTICLE	IF	CITATIONS
307	Epidemiological Impact of Tenofovir Gel on the HIV Epidemic in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 207-210.	2.1	51
308	Short Communication Decreased Incidence of Dual Infections in South African Subtype C-Infected Women Compared to a Cohort Ten Years Earlier. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1167-1172.	1.1	7
309	Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection. <i>Journal of Virology</i> , 2011, 85, 208-216.	3.4	66
310	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. <i>Journal of Virology</i> , 2011, 85, 7719-7729.	3.4	54
311	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. <i>PLoS ONE</i> , 2011, 6, e23532.	2.5	137
312	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. <i>Aids</i> , 2010, 24, 819-831.	2.2	195
313	Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. <i>Virology</i> , 2010, 396, 213-225.	2.4	26
314	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. <i>Virology</i> , 2010, 402, 187-196.	2.4	95
315	Screening for "window" period acute HIV infection among pregnant women in rural South Africa. <i>HIV Medicine</i> , 2010, 11, 661-665.	2.2	30
316	AIDS research must link to local policy. <i>Nature</i> , 2010, 463, 733-734.	27.8	13
317	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. <i>South African Medical Journal</i> , 2010, 100, 808.	0.6	10
318	Inclusion of Adolescent Women in Microbicide Trials: A Public Health Imperative!. <i>Public Health Ethics</i> , 2010, 3, 39-50.	1.0	13
319	Fluidity of HIV-1-Specific T-Cell Responses during Acute and Early Subtype C HIV-1 Infection and Associations with Early Disease Progression. <i>Journal of Virology</i> , 2010, 84, 12018-12029.	3.4	26
320	HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection. <i>Journal of Clinical Microbiology</i> , 2010, 48, 281-285.	3.9	9
321	Preventing HIV Infection in Women: A Global Health Imperative. <i>Clinical Infectious Diseases</i> , 2010, 50, S122-S129.	5.8	97
322	Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa " missed opportunities for early diagnosis of HIV infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 533-537.	1.2	35
323	APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. <i>Aids</i> , 2010, 24, 195-204.	2.2	61
324	Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. <i>Future Microbiology</i> , 2010, 5, 527-529.	2.0	19

#	ARTICLE	IF	CITATIONS
325	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. <i>Science</i> , 2010, 329, 1168-1174.	12.6	2,239
326	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. <i>New England Journal of Medicine</i> , 2010, 362, 697-706.	27.0	608
327	Microbicides & their implications in HIV prevention. <i>Indian Journal of Medical Research</i> , 2010, 132, 656-9.	1.0	7
328	Re: "Enhancement of HIV Infection by Cellulose Sulfate," by Tao et al.. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 373-373.	1.1	1
329	Human TRIM5 α Expression Levels and Reduced Susceptibility to HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1657-1663.	4.0	46
330	Association of HIV-Specific and Total CD8+ T Memory Phenotypes in Subtype C HIV-1 Infection with Viral Set Point. <i>Journal of Immunology</i> , 2009, 182, 4751-4761.	0.8	75
331	Commentary: Spatial clustering of HIV infection: providing clues for effective HIV prevention. <i>International Journal of Epidemiology</i> , 2009, 38, 1016-1017.	1.9	8
332	Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. <i>Journal of Virology</i> , 2009, 83, 3556-3567.	3.4	354
333	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. <i>PLoS Pathogens</i> , 2009, 5, e1000598.	4.7	213
334	Interleukin-10 Promoter Polymorphisms Influence HIV-1 Susceptibility and Primary HIV-1 Pathogenesis. <i>Journal of Infectious Diseases</i> , 2009, 200, 448-452.	4.0	72
335	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. <i>Journal of Virology</i> , 2009, 83, 11265-11274.	3.4	93
336	Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. <i>Journal of Virology</i> , 2009, 83, 470-478.	3.4	63
337	Salim "Slim" Abdool Karim: Attacking AIDS in South Africa. <i>Journal of Experimental Medicine</i> , 2009, 206, 2306-2307.	8.5	0
338	Scientists stand by decision to join Mbeki's AIDS panel. <i>Nature</i> , 2009, 457, 379-379.	27.8	1
339	Disclosure of HIV status: experiences of patients enrolled in an integrated TB and HAART pilot programme in South Africa. <i>African Journal of AIDS Research</i> , 2009, 8, 1-6.	0.9	19
340	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet, The</i> , 2009, 374, 921-933.	13.7	414
341	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet, The</i> , 2009, 374, 1023-1031.	13.7	214
342	PRO 2000: next steps for microbicide development. <i>Future Virology</i> , 2009, 4, 317-320.	1.8	2

#	ARTICLE	IF	CITATIONS
343	Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges. <i>HIV Therapy</i> , 2009, 3, 3-6.	0.6	29
344	Interventions with youth in high-prevalence areas. , 2009, , 407-443.		9
345	Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection. <i>Virology Journal</i> , 2008, 5, 141.	3.4	4
346	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	3.4	548
347	Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection. <i>Journal of Virology</i> , 2008, 82, 115-125.	3.4	108
348	Apnea and its possible relationship to immunization in ex-premature infants. <i>Vaccine</i> , 2008, 26, 3410-3413.	3.8	15
349	The influence of AIDS stigma and discrimination and social cohesion on HIV testing and willingness to disclose HIV in rural KwaZulu-Natal, South Africa. <i>Global Public Health</i> , 2008, 3, 351-365.	2.0	42
350	HIV Risk Behaviors in Sub-Saharan Africa and Northern Thailand: Baseline Behavioral Data From Project Accept. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 309-319.	2.1	44
351	Relationship between Levels of Inflammatory Cytokines in the Genital Tract and CD4 ⁺ Cell Counts in Women with Acute HIV ¹ Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 710-714.	4.0	71
352	Transmission of HIV-1 CTL Escape Variants Provides HLA-Mismatched Recipients with a Survival Advantage. <i>PLoS Pathogens</i> , 2008, 4, e1000033.	4.7	129
353	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. <i>Journal of Virology</i> , 2008, 82, 1860-1869.	3.4	142
354	HIV Transmission and its Prevention in Africa. , 2008, , 565-575.		0
355	Anaemia in Acute HIV-1 Subtype C Infection. <i>PLoS ONE</i> , 2008, 3, e1626.	2.5	15
356	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. <i>PLoS ONE</i> , 2008, 3, e1954.	2.5	175
357	Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection. <i>Journal of Virology</i> , 2007, 81, 6187-6196.	3.4	262
358	Response to Brown et al., "Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe". <i>Aids</i> , 2007, 21, 2356-2357.	2.2	0
359	Utilizing nucleic acid amplification to identify acute HIV infection. <i>Aids</i> , 2007, 21, 653-655.	2.2	11
360	Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 316-321.	1.1	25

#	ARTICLE	IF	CITATIONS
361	Practice Brief: Adolescents and HIV Clinical Trials: Ethics, Culture, and Context. <i>Journal of the Association of Nurses in AIDS Care</i> , 2007, 18, 78-82.	1.0	25
362	Global Epidemiology of HIV-AIDS. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 1-17.	5.1	24
363	Diverse approaches useful for microbicide trials. <i>Nature</i> , 2007, 449, 24-24.	27.8	8
364	Opportunities for treating sexually transmitted infections and reducing HIV risk in rural South Africa. <i>Journal of Advanced Nursing</i> , 2007, 60, 377-383.	3.3	19
365	Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. <i>BMC Pediatrics</i> , 2007, 7, 13.	1.7	159
366	HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa. <i>South African Medical Journal</i> , 2007, 97, 190.	0.6	2
367	HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. <i>Lancet, The</i> , 2006, 368, 489-504.	13.7	496
368	Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa. <i>PLoS Medicine</i> , 2006, 3, e180.	8.4	43
369	Modeling the Impact of a Partially Effective HIV Vaccine on HIV Infection and Death Among Women and Infants in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 219-225.	2.1	26
370	Durban 2000 to Toronto 2006: The evolving challenges in implementing AIDS treatment in Africa. <i>Aids</i> , 2006, 20, N7-N9.	2.2	6
371	Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosisâ€“HIV-co-infected patients in resource-constrained settings. <i>Aids</i> , 2006, 20, 302-303.	2.2	9
372	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. <i>Journal of Virology</i> , 2006, 80, 11776-11790.	3.4	334
373	TB treatment outcomes following directly-observed treatment at an urban outpatient specialist TB facility in South Africa. <i>Tropical Doctor</i> , 2006, 36, 23-25.	0.5	6
374	The Impact of Incident and Prevalent Herpes Simplex Virus-2 Infection on the Incidence of HIV-1 Infection Among Commercial Sex Workers in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 333-339.	2.1	67
375	Knowledge and acceptability of HAART among TB patients in Durban, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2005, 17, 767-772.	1.2	10
376	Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 285-291.	1.1	24
377	The African Experience. , 2005, , 351-373.		2
378	Incidence of HIVâ€“1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIVâ€“1 Subtype Câ€“1-Infected Female Sex Workers. <i>Journal of Infectious Diseases</i> , 2004, 190, 1355-1359.	4.0	119

#	ARTICLE	IF	CITATIONS
379	Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8 + T Cells: Correlation with Viral Load. <i>Journal of Virology</i> , 2004, 78, 3233-3243.	3.4	202
380	A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 929-934.	2.1	58
381	Novel and Promiscuous CTL Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C HIV Type 1 Infection from Southern Africa. <i>Journal of Immunology</i> , 2004, 173, 4607-4617.	0.8	49
382	Ethical Challenges in International HIV Prevention Research. <i>Accountability in Research</i> , 2004, 11, 49-61.	2.4	23
383	Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. <i>Clinical Infectious Diseases</i> , 2004, 38, S421-S428.	5.8	27
384	Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. <i>Tropical Medicine and International Health</i> , 2004, 9, 1216-1221.	2.3	20
385	Dual HIV-1 infection associated with rapid disease progression. <i>Lancet, The</i> , 2004, 363, 619-622.	13.7	189
386	Medical education after the first decade of democracy in South Africa. <i>Lancet, The</i> , 2004, 363, 1395.	13.7	8
387	Implementing antiretroviral therapy in resource-constrained settings. <i>Aids</i> , 2004, 18, 975-979.	2.2	33
388	Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C-infected seronegative women. <i>Aids</i> , 2004, 18, 2096-2098.	2.2	6
389	Antiretroviral therapy: challenges and options in South Africa. <i>Lancet, The</i> , 2003, 362, 1499.	13.7	5
390	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 133-144.	1.1	113
391	The Acceptability of an Investigational Vaginal Microbicide, PRO 2000 Gel, among Women in a Phase I Clinical Trial. <i>Journal of Women's Health</i> , 2003, 12, 655-666.	3.3	91
392	Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial. <i>Sexually Transmitted Infections</i> , 2003, 79, 208-213.	1.9	55
393	Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. <i>Aids</i> , 2003, 17, 321-329.	2.2	83
394	Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. <i>Aids</i> , 2003, 17, 2245-2252.	2.2	249
395	The Impact of Migration on HIV-1 Transmission in South Africa. <i>Sexually Transmitted Diseases</i> , 2003, 30, 149-156.	1.7	362
396	Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 482-490.	2.1	59

#	ARTICLE	IF	CITATIONS
397	High Incidence of HIV-1 in South Africa Using a Standardized Algorithm for Recent HIV Seroconversion. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 531-535.	2.1	46
398	Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. <i>Journal of Virology</i> , 2002, 76, 2233-2244.	3.4	111
399	The evolving HIV epidemic in South Africa. <i>International Journal of Epidemiology</i> , 2002, 31, 37-40.	1.9	54
400	Incidence of Sexually Transmitted Infections Among HIV-Positive Sex Workers in KwaZulu-Natal, South Africa. <i>Sexually Transmitted Diseases</i> , 2002, 29, 721-724.	1.7	18
401	A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 875-878.	3.0	31
402	Vertical HIV transmission in South Africa: translating research into policy and practice. <i>Lancet, The</i> , 2002, 359, 992-993.	13.7	21
403	Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. <i>Lancet, The</i> , 2002, 360, 971-977.	13.7	755
404	The fate of free male condoms distributed to the public in South Africa. <i>Aids</i> , 2001, 15, 789-793.	2.2	21
405	Clinical testing of microbicides: a global research priority. <i>Aids</i> , 2001, 15, 929-930.	2.2	1
406	Estimating HIV incidence rates from age prevalence data in epidemic situations. <i>Statistics in Medicine</i> , 2001, 20, 2003-2016.	1.6	66
407	Conserved Domains of Subtype C Nef from South African HIV Type 1-Infected Individuals Include Cytotoxic T Lymphocyte Epitope-Rich Regions. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1681-1687.	1.1	20
408	Microbicide Research and Development—Where To?. <i>HIV Clinical Trials</i> , 2001, 2, 185-192.	2.0	6
409	Characterization of Full-Length HIV Type 1 Subtype C Sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1527-1531.	1.1	52
410	Estimating HIV incidence rates from age prevalence data in epidemic situations. <i>Statistics in Medicine</i> , 2001, 20, 2003-2016.	1.6	3
411	Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. <i>Aids</i> , 2000, 14, 2553-2557.	2.2	40
412	Availability of Condoms in Urban and Rural Areas of KwaZulu-Natal, South Africa. <i>Sexually Transmitted Diseases</i> , 2000, 27, 353-357.	1.7	18
413	Syndrome packets and health worker training improve sexually transmitted disease case management in rural South Africa: randomized controlled trial. <i>Aids</i> , 2000, 14, 2769-2779.	2.2	43
414	Globalization, Ethics, and AIDS Vaccines. <i>Science</i> , 2000, 288, 2129-2129.	12.6	5

#	ARTICLE	IF	CITATIONS
415	Inadequate Treatment for Sexually Transmitted Diseases in the South African Private Health Sector. International Journal of STD and AIDS, 1999, 10, 324-327.	1.1	26
416	Short course antiretroviral regimens to reduce maternal transmission of HIV. BMJ: British Medical Journal, 1999, 318, 479-480.	2.3	11
417	Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. Aids, 1999, 13, 1511-1515.	2.2	44
418	STD Syndrome Packets: Improving Syndromic Management of Sexually Transmitted Diseases In Developing Countries. Sexually Transmitted Diseases, 1999, 26, 152-156.	1.7	14
419	HIV infection and asymptomatic sexually transmitted infections in a rural South African community. International Journal of STD and AIDS, 1998, 9, 548-550.	1.1	37
420	Sexually Transmitted Infections Among Sex Workers in KwaZulu-Natal, South Africa. Sexually Transmitted Diseases, 1998, 25, 346-349.	1.7	81
421	Improving quality of sexually transmitted disease case management in rural South Africa. Aids, 1998, 12, 2329-2335.	2.2	38
422	Sexually Transmitted Disease Syndromes in Rural South Africa. Sexually Transmitted Diseases, 1998, 25, 20-23.	1.7	29
423	South Africa. Lancet, The, 1997, 349, 1537-1545.	13.7	19
424	Potential savings from generic prescribing and generic substitution in South Africa. Health Policy and Planning, 1996, 11, 198-202.	2.7	39
425	Sex difference in measles fatality after introduction of new measles vaccine. Lancet, The, 1994, 343, 1366-1367.	13.7	11
426	Seroprevalence of HIV infection in rural South Africa. Aids, 1992, 6, 1535-1540.	2.2	93
427	Household Clustering and Intra-Household Transmission Patterns of Hepatitis B Virus Infection in South Africa. International Journal of Epidemiology, 1991, 20, 495-503.	1.9	46
428	The Prevalence and Transmission of Hepatitis B Virus Infection in Urban, Rural and Institutionalized Black Children of Natal/KwaZulu, South Africa. International Journal of Epidemiology, 1988, 17, 168-173.	1.9	44
429	Socio-Medical Indicators of Health in South Africa. International Journal of Health Services, 1986, 16, 163-178.	2.5	13
430	Overview of the book. , 0, , 45-54.		2
431	New prevention strategies under development and investigation. , 0, , 268-282.		3
432	The future of the HIV epidemic in South Africa. , 0, , 585-590.		0

#	ARTICLE	IF	CITATIONS
433	Cost-Effectiveness of Point-of-Care Testing with Task-Shifting for HIV Care in South Africa: A Modelling Study. SSRN Electronic Journal, 0, , .	0.4	0
434	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. Transactions of the Royal Society of South Africa, 0, , 1-4.	1.1	2
435	HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. Journal of Virology, 0, , .	3.4	0